MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:34Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Corticosteroids]]
			[[Category:Glucocorticoids]]
			[[Category:Immunosuppressants]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #135

2026-05-23T03:51:56Z

parser-claude batch MedTemplate pre-fill, Top 300 #135

New page

{{MedTemplate
| generic = Methylprednisolone
| brand = Medrol (oral), Solu-Medrol (IV/IM), Depo-Medrol (depot injection)
| structure =
| classes = [[:Category:Corticosteroids|Corticosteroid]], [[:Category:Glucocorticoids|Glucocorticoid (intermediate-acting)]], [[:Category:Immunosuppressants|Immunosuppressant]]
| uses = <vote slug="autoimmune-flare-use">Autoimmune disease flare</vote>, <vote slug="asthma-copd-exacerbation-use">Asthma/COPD exacerbation (IV in severe disease)</vote>, <vote slug="ms-relapse-use">Multiple sclerosis relapse (high-dose IV pulse)</vote>, <vote slug="transplant-rejection-use">Transplant rejection</vote>, <vote slug="intra-articular-arthritis-use">Intra-articular for arthritis (Depo-Medrol)</vote>
| starting_dose = PO Medrol Dosepak (5-day taper from 24 mg to 4 mg) is the prototypic short-course outpatient regimen; IV pulse 1 g daily for 3-5 days for MS relapse; intra-articular 4-80 mg per joint q1-5 weeks
| preparations = 2, 4, 8, 16, 32 mg oral tablets; 40, 125, 500, 1000 mg IV vials; Depo-Medrol 20, 40, 80 mg/mL IM depot
| fda_max = Indication-specific
| pill_id =
| routes = Oral, IM, IV, intra-articular, intrathecal (rare and controversial)
| onset = IV pulse: hours; PO: hours; intra-articular: days
| duration = Biologic 12-36 hours (intermediate-acting); Depo-Medrol depot weeks
| halflife = Plasma 2-3 hours; biologic ~18-36 hours<ref name="medrol-label">FDA Prescribing Information, Medrol (methylprednisolone), Pfizer/Pharmacia, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011153s080lbl.pdf</ref>
| bioavailability = ~80-99% (oral)<ref name="medrol-label" />
| pregnancy = Use when benefits outweigh; small association with oral clefts in first trimester debated.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="methylprednisolone-mech-claim">Methylprednisolone is a synthetic glucocorticoid agonist intermediate in potency between prednisone/prednisolone and dexamethasone, with negligible mineralocorticoid activity (less sodium/water retention than hydrocortisone).</vote> Activates the glucocorticoid receptor to broadly remodel inflammatory, immune, and metabolic transcription. Unlike prednisone, it does not require hepatic activation, making it the preferred oral choice in severe hepatic dysfunction<ref name="medrol-label" />.
}}

== References ==
<references />

Methylprednisolone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #135